Exelixis, Inc. Reports Updated Phase 2 Data for XL184 in Patients With Recurrent Glioblastoma to Be Presented at American Society of Clinical Oncology

March 17, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

(RTTNews) - Exelixis, Inc. (EXEL: News ) on Thursday reported promising interim data from an ongoing phase 2 trial of XL184 in patients with recurrent glioblastoma, the most common and aggressive form of brain cancer.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase 2

Exelixis, Inc.